Kyoto-based medical-device startup Quadlytics has established its Australian subsidiary, Quadlytics Pty Ltd, in Melbourne, strengthening Victoria’s position as a destination for global medtech companies scaling into international markets.
Quadlytics is developing a software-as-a-medical-device (SaMD), used with a wearable ECG sensor, to support people living with epilepsy. Unlike technologies that detect seizures after they begin, Quadlytics’ solution uses AI to analyse heart-rate variability and warn users before a seizure occurs, giving patients, families and carers valuable time to move to safety.
The company has based its Australian team at Melbourne Connect at the University of Melbourne, placing it close to Victoria’s world-class epilepsy research and clinical community. From this base, Quadlytics is progressing a Japan–Australia clinical trial and advancing its pathway towards Therapeutic Goods Administration (TGA) approval, with leading Victorian epilepsy specialists supporting the work as advisors.
Australia is Quadlytics’ most important first international market, with Victoria serving as the launchpad for its global growth.
Kohei Hayashi, CEO, Quadlytics, said Melbourne had been a strategic choice for the company’s international expansion.
Establishing our presence in Melbourne has been a pivotal step in our global growth. Victoria offers a strong environment for medtech startups, with real closeness between startups and the clinical community — and world-class epilepsy research that matters to us. Invest Victoria's practical support and local connections gave us the confidence to invest here.
Invest Victoria supported Quadlytics as it established its Melbourne presence, providing practical assistance with setting up the subsidiary, connecting the company with local partners and advisors, and helping it access skilled local talent. This support has helped Quadlytics build its on-the-ground capability in Victoria and deepen collaboration with local partners as it advances clinical and commercial milestones.
Quadlytics’ investment highlights Victoria’s competitive strengths in medtech, digital health, clinical research and commercialisation support for innovative global companies.
Explore Victoria’s Medtech and Pharma sector and discover how Invest Victoria can help your business establish, grow and connect with the right partners, talent and opportunities.
